Related Experiment Video
Updated: Jun 13, 2025
08:27
Large-Scale Multi-Omics Genome-Wide Association Studies Mo-GWAS: Guidelines for Sample Preparation and Normalization
Published on: July 27, 2021
3.6K
The causal relationship between CSF metabolites and GBM: a two-sample mendelian randomization analysis.
Haijun Bao1,2, Yiyang Chen1, Zijun Meng1
1Department of Forensic Medicine, First College for Clinical Medicine, Xuzhou Medical University, 84 West Huaihai Rd, Xuzhou, Jiangsu, 221000, China.
BMC Cancer
|September 9, 2024
Summary
This study used Mendelian randomization to identify cerebrospinal fluid (CSF) metabolites causally linked to glioblastoma multiforme (GBM). Several metabolites were associated with increased or decreased GBM risk, offering insights into disease mechanisms.
Area of Science:
- Neuro-oncology
- Metabolomics
- Genetics
Background:
- Glioblastoma multiforme (GBM) is an aggressive brain tumor with poor outcomes.
- Understanding cerebrospinal fluid (CSF) metabolites is key to identifying GBM biomarkers and pathways.
Purpose of the Study:
- To investigate the causal relationship between CSF metabolites and GBM using Mendelian randomization (MR).
- To identify potential CSF metabolite biomarkers for GBM diagnosis and therapeutic targets.
Main Methods:
- Mendelian randomization (MR) analysis was performed on 338 CSF metabolites and GBM data.
- Genome-wide association study summary data and FinnGen data were utilized.
- Inverse Variance Weighted, MR-Egger, Weighted Median, Simple Mode, and Weighted Mode methods were applied.
Main Results:
- A causal relationship was found between 12 identified CSF metabolites and GBM.
- Metabolites like Alpha-tocopherol and Valine were associated with increased GBM risk.
- N1-methylinosine and Stachydrine were associated with decreased GBM risk.
Conclusions:
- This research highlights the complex interaction between CSF metabolites and GBM pathogenesis.
- Findings offer new perspectives for diagnostic advancements and targeted therapies for GBM.
- Further research may improve GBM management and patient outcomes.
